Condition: Systemic Sclerosis · Sponsor: University Hospital, Toulouse
Ischemic digital ulcers (DUs) are a frequent complication in systemic sclerosis with a major impact on hand function and quality of life. Digital injection of cultured adipose-derived stromal cell (AdMSC) constitutes a promising approach to treat scleroderma-induced refractory ischemic DUs where no alternative therapy is validated. The aim of this phase 2 study is to compare efficacy and safety of digital injection of AdMSC versus placebo for healing refractory active ischemic digital ulcers in patients with systemic sclerosis.
This description comes directly from the study's public registry record.
Grégory PUGNET, MD, PHD · 05 61 77 71 26 · pugnet.g@chu-toulouse.fr
Always discuss trial participation with your own doctor first.
| Grenoble Hospital | Grenoble, France | Not Yet Recruiting |
| Lille Hopsital | Lille, France | Not Yet Recruiting |
| Marseille Hospital | Marseille, France | Not Yet Recruiting |
| Montpellier Hospital | Montpellier, France | Not Yet Recruiting |
| Nantes Hospital | Nantes, France | Not Yet Recruiting |
| Poitiers Hospital | Poitiers, France | Not Yet Recruiting |
| CHU de Toulouse - Hôpital PURPAN-TSA | Toulouse, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04356755